H. Lundbeck A/S has initiated phase I clinical trials with the pharmaceutical candidate Lu AA24493 to investigate safety, tolerability and the pharmacokinetic profile of the compound in patients suffering from acute ischemic stroke.

Worldwide Pharmaceutical Sales Increased 19.6 Percent. Worldwide Medical Products Sales Increased 12.0 Percent. International Nutritionals Sales Increased 15.6 Percent. Company Confirms Earnings-Per-Share Outlook for 2007 and 2008.

Pharmion Corporation (Nasdaq: PHRM) today announced the initiation of an international pivotal Phase 3 clinical trial evaluating amrubicin, the Company's third-generation synthetic anthracycline, in the treatment of second-line small cell lung cancer (SCLC). The randomized, controlled, multi-center study will compare amrubicin to topotecan, the only approved chemotherapy for second-line treatment of SCLC in the US and EU. Enrollment in the study of 480 patients is underway.

Bayer Schering Pharma AG, Germany, announced that top-line, three-year data from the CAMMS223 Phase II clinical trial comparing alemtuzumab with Rebif® (interferon beta-1a) for the treatment of multiple sclerosis were presented this weekend at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Prague. The results come from an analysis conducted at 36 months following treatment of 334 patients in the three-year trial.

Pfizer Inc and Sermo, the nation's largest online physician community, today announced a strategic collaboration designed to redefine the way physicians in the U.S. and the healthcare industry work together to improve patient care. Sermo is a Web-based community where physicians share observations from daily practice, discuss emerging trends and provide new insights into medications, devices and treatments.

Bristol-Myers Squibb Company (NYSE: BMY) will announce results for the third quarter of 2007 on Thursday, October 25. During a conference call on October 25 at 10:30 a.m. (ET), financial information will be reviewed and company executives will address inquiries from investors and analysts.

Boehringer Ingelheim has been ranked first among the top employers in the pharmaceutical and biopharmaceutical industry according to the 2007 Top Employers survey conducted by Science. Science's annual survey polls employees in biotechnology, biopharmaceutical, pharmaceutical, and related industries.